Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus

Clinical Nutrition

Volumn 19, Issue 5, 2000, Pages 367-370

  De Luis, D A ^a   Romero, E ^a   Aller, R ^a   Izaola, O ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

Cerivastatin; Hypercholesterolaemia; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTACID AGENT; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; CERIVASTATIN; CHOLESTEROL; CIMETIDINE; COLESTYRAMINE; CREATINE KINASE; DEXTRAN SULFATE; DIGOXIN; ERYTHROMYCIN; GLUCOSE; GLUCOSE OXIDASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; SULFONYLUREA; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; LIPID METABOLISM; LIVER DYSFUNCTION; LOW BACK PAIN; MALE; MICROALBUMINURIA; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROSPECTIVE STUDY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0033765172     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1054/clnu.2000.0127     Document Type: Article

References (20)

1. The lipid research clinics coronary primary prevention trials results
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study
3. Prevention of coronary heart disease with pravastatin in men with hypercholesteronemia
4. Diabetes and atherosclerosis: Epidemiological considerations
5. Cerivastatin a new potent synthetic HMGCoA reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesteronemia
6. Management of dyslipemia in adults with diabetes
7. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesteronemia. International cerivastatin
8. Efficacy and safety of 300 micrograms and 400 micrograms erivastatin once daily in patients with primary hypercholesteronemia: A multicentre, randomized, double blind, placebo-controlled study
9. Efficacy and safety of cerivastatin in primary hypercholesteronemia: A long term comparative titration study with simvastatin
10. Biopharmaceutical profile of cerivastatin: A novel HMGCoA reductase inhibitor
11. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8 mg dose of cerivastatin in patients with primary hypercholesteronemia
12. Influence of the antiacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin
13. Influence of cholestyramine on the pharmacokinetics of cerivastatin
14. Lack of pharmacokinetic interation between cerivastatin, a new HMGCoA reductase inhibitor, and digoxin
15. No pharmacokinetics or pharmacodynamic interaction between cerivastatin and warfarin
16. Influence of erythromicin pre and co-treatment on single-dose pharmacokinetics of the HMGCoA reductase inhibitor cerivastatin
17. Clinical efficiency and safety of cerivastatin: Phase IIb/III studies
18. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid leves, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
19. Standard of medical care for patients with diabetes mellitus (Position Statement)